Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
1 Front Matter; 2 Summary; 3 1 Introduction; 4 2 Profile of Rare Diseases; 5 3 Regulatory Framework for Drugs for Rare Diseases; 6 4 Discovery Research for Rare Diseases and Orphan Product Development; 7 5 Development of New Therapeutic Drugs and Biologics for Rare Diseases; 8 6 Coverage and Reimbursement: Incentives and Disincentives for Product Development; 9 7 Medical Devices: Research and Development for Rare Diseases; 10 8 Toward an Integrated Approach to Accelerating Research and Product Development for Rare Diseases; 11 References; 12 Appendix A: Study Activities; 13 Appendix B: Innovation and the Orphan Drug Act, 1983-2009: Regulatory and Clinical Characteristics of Approved Orphan Drugs; 14 Appendix C: Medicare Part D Coverage and Reimbursement of Orphan Drugs; 15 Appendix D: Glossary, Abbreviations, and Public Laws; 16 Appendix E: Rare Diseases Clinical Research Network; 17 Appendix F: Advocacy Group Approaches to Accelerating Research and Product Development: Illustrative Examples; 18 Appendix G: Committee and Staff Biographies; 19 Index
National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
Institute of Medicine, Board on Health Sciences Policy, Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), Thomas F. Boat, Marilyn J. Field
and Medicine National Academies of Sciences, Engineering, Institute of Medicine, and Families Board on Children, Youth, Board on the Health of Select Populations, Committee to Evaluate the Supplemental Security Income Disability Program for Children with Mental Disorders, Joel T. Wu, Thomas F. Boat
Institute of Medicine, Board on Health Sciences Policy, and Practice Committee on Conflict of Interest in Medical Research, Education, Marilyn J. Field, Bernard Lo
Institute of Medicine, Board on Health Sciences Policy, Committee on Postmarket Surveillance of Pediatric Medical Devices, Hugh Tilson, Marilyn J. Field
Institute of Medicine, Board on Neuroscience and Behavioral Health, Committee on Incorporating Research into Psychiatry Residency Training, Thomas F. Boat, Kathleen M. Patchan, Michael T. Abrams
Institute of Medicine, Board on Health Sciences Policy, Committee on Palliative and End-of-Life Care for Children and Their Families, Richard E. Behrman, Marilyn J. Field